XML 41 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Revenue - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2017
Dec. 31, 2016
Dec. 31, 2015
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2018
Aug. 31, 2022
Aug. 31, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue         $ 1,125   $ 1,125        
Contract asset recorded as accounts receivable and unbilled receivable               $ 2,000      
Negotiated settlement of receivable recorded as accounts receivable, net       $ 1,500   $ 1,500          
2015 Sanofi Collaboration Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaborative arrangement, rights and obligations           Sanofi had the exclusive rights and responsibility for the development, commercialization and manufacture of collaboration products resulting from the collaboration. Sanofi was obligated to use commercially reasonable efforts to commercialize at least one collaboration product for each target, within certain countries, upon regulatory approval of such product.          
Collaboration arrangement, initial fee paid     $ 8,000                
Annual technology access and development fee   $ 9,000 $ 1,000                
Remaining unrecognized revenue to be recognized                     $ 3,000
Revenue, remaining performance obligation, expected timing of satisfaction, explanation           the Company had remaining unrecognized revenue of $3.0 million from the Agreement to be recognized over the remaining term (August 2017 through December 2020)          
Revenue       0 0 $ 0 0        
Deferred revenue recognized           0   0 $ 2,000    
Contract asset recorded as accounts receivable and unbilled receivable               $ 2,000      
Negotiated settlement of receivable recorded as accounts receivable, net       1,500   1,500          
2015 Sanofi Collaboration Agreement | Forecast                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Negotiated settlement of receivable recorded as accounts receivable, net                   $ 1,500  
2017 Genentech Collaboration Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue       $ 0 $ 1,100 $ 0 $ 1,100        
Collaborative arrangement, collaboration target term 2 years                    
Collaboration target access fee $ 4,500               $ 1,500